Selecta Biosciences Inc

NASDAQ:SELB  
3.96
+0.01 (+0.25%)
Twitter Share  Facebook Share StockTwits Share

Search For a Symbol

Market Cap (Intraday)455.70M
Current PEN/A
Forward PE N/A
2yr Forward PE N/A
See more stats
Estimates Current Quarter
Revenue$12.19 Million
Adjusted EPS-$0.07
See more estimates
10-Day MA$4.10
50-Day MA$4.22
200-Day MA$4.07
See more pivots

Selecta Biosciences Inc Stock, NASDAQ:SELB

480 Arsenal Way, 65 Grove Street, Watertown, Massachusetts 02472
United States of America
Phone: +1.617.923.1400
Number of Employees: 43

Description

Selecta Biosciences, Inc. operates as a clinical-stage biopharmaceutical company, which engages in the research and development of nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases. It produces the Synthetic Vaccine Particles (SVP) platform for immune tolerance and immune stimulation. The firm's proprietary pipeline includes SVP-enabled enzyme, oncology and gene therapies. The company was founded by Omid C. Farokhzad, Robert S. Langer Jr., and Ulrich von Andrian in 2007 and is headquartered in Watertown, MA.